During an Institute for Value-Based Medicine event in November 2024, experts in oncology highlighted how insurance coverage disparities and financial burdens limit equitable cancer care. In this interview, Susan Escudier, MD, FACP, medical oncologist and vice president of value-based care […]
The Need for Payer Support in Overcoming Cancer Care Disparities Read More »
Patients with extensive-stage small cell lung cancer (ES-SCLC) saw significant survival benefits when treated with either PD-1 or PD-L1 inhibitors combined with chemotherapy, according to a new meta-analysis.1 Researchers found no significant difference in OS and PFS for patients with
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer Read More »
At an Institute for Value-Based Medicine event in November 2024, experts discussed how social determinants of health worsen cancer care disparities in Houston, Texas. In this interview from the event, Susan Escudier, MD, FACP, medical oncologist and vice president of
Addressing Financial Toxicity and Clinical Trial Disparities in Community Oncology Read More »
Therapeutic inertia occurs when a patient’s treatment is not adjusted in a timely manner after not meeting their treatment goals. In diabetes and cardiometabolic care, addressing therapeutic inertia is essential to ensuring patients receive evidence-based treatments like sodium glucose co-transporter
Overcoming Barriers to Guideline-Directed Cardiometabolic Care Read More »
The top population health article of 2024 focused on 5 drugs in shortage as we go into the new year. | Image credit: MQ-Illustrations – stock.adobe.com The top population health news of 2024 included efforts to reduce out-of-pocket drug costs,
Top 5 Most-Read Population Health Articles of 2024 Read More »
The top IVBM® coverage of 2024 focused on improving care delivery, addressing obesity, and more. | Image Credit: © AJMC® In 2024, the Institute for Value-Based Medicine® (IVBM®) brought together leading experts to explore transformative strategies in health care. From
The Top 5 Institute for Value-Based Medicine Coverage of 2024 Read More »
The top heart failure articles of 2024 reflect a growing focus on innovative treatments and preventative strategies to improve patient outcomes, especially for heart failure with preserved ejection fraction (HFpEF). From surgical interventions and medication breakthroughs to understanding the impacts
Top 5 Most-Read Heart Failure Articles of 2024 Read More »
Research in Duchenne muscular dystrophy (DMD) has seen significant growth over the past 2 decades, according to a bibliometric analysis published in Frontiers in Immunology.1 The study, which examined more than 9000 publications between 2004 and 2023, highlights evolving research
Study Highlights Trends, Emerging Innovations in DMD Research Read More »
Lexicon Pharmaceuticals received a complete response letter (CRL) from the FDA today, rejecting the company’s application for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD), according
FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus Read More »
The Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) program is a team-based care model designed to address cardiovascular, kidney, and metabolic health risks in patients with type 2 diabetes or prediabetes. Developed by the University Hospitals Harrington
Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes Read More »
